To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib ...

A new editorial paper was published in Oncoscience (Volume 11) on May 6, 2024, entitled, "Restoring our ubiquitination machinery to overcome resistance in cancer therapy." In this new editorial, ...

While traditional induction therapy for newly diagnosed stage 2 myeloma often focuses on combinations of proteasome inhibitors, immunomodulatory drugs, and steroids, these newer immunotherapy classes ...

Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a ...

Restoring P53's autonomous anti-cancer function through P53 mRNA delivery is a promising anti-tumor strategy. Yet, in tumors harboring mutant P53, the existing mutant P53 (Mutp53) would interferes ...

When blood cancer in children progresses particularly aggressively, it is often due to a genetic defect: a gene fusion, such ...

Recent research from the lab of Dr. Nicolas Lehrbach, an Assistant Professor in the Basic Sciences Division at Fred Hutch, discovered that altering nucleotide metabolism may bypass proteasome defects ...